<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03248297</url>
  </required_header>
  <id_info>
    <org_study_id>CHI UAB MISP # 54628</org_study_id>
    <nct_id>NCT03248297</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophlaxis for High-risk Laboring Women in Low Income Countries</brief_title>
  <official_title>Azithromycin With or Without Amoxicillin to Prevent Peripartum Infection and Sepsis in Laboring High-risk Women: 3-Arm RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study, performed over a course of 3 years in 5 collaborating hospitals in Cameroon,&#xD;
      Africa, will randomize 750 women in labor with prolonged rupture of membranes ≥ 8 hours or&#xD;
      prolonged labor ≥ 18 hours to identical oral regimens of 1 gram of azithromycin, 1 gram of&#xD;
      azithromycin+2 grams of amoxicillin or placebo. Women will be followed to ascertain maternal&#xD;
      infectious outcomes and perinatal outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 3-arm study is a large randomized clinical trial designed to evaluate the comparative&#xD;
      effectiveness and safety of single dose oral azithromycin or combined&#xD;
      azithromycin+amoxicillin compared to placebo for the prevention of peripartum infections and&#xD;
      sepsis in laboring women. We have previously shown the effectiveness of azithromycin for&#xD;
      extended spectrum antibiotic prophylaxis in addition to the standard cephalosporin alone for&#xD;
      reduction of post-cesarean infections. In LICs, the fraction of maternal infection and sepsis&#xD;
      from cesarean delivery is minimal. Therefore, it is necessary to evaluate strategies aimed at&#xD;
      reducing these morbidities in women who have vaginal births. There is an increased risk of&#xD;
      infection in women who have prolonged labor or prolonged rupture of membranes. Drawing from&#xD;
      our findings with azithromycin-based extended antibiotic prophylaxis for cesarean delivery,&#xD;
      we propose to adapt the intervention and evaluate a single oral dose of azithromycin (with or&#xD;
      without oral amoxicillin) to prevent maternal peripartum infection and sepsis. This study,&#xD;
      performed over a course of 3 years in 5 collaborating hospitals in Cameroon, Africa, will&#xD;
      randomize 750 women in labor with prolonged rupture of membranes ≥ 8 hours or prolonged labor&#xD;
      ≥18 hours to 1 gram of oral azithromycin, 1 gram of azithromycin+2 grams of amoxicillin,&#xD;
      compared to usual care (placebo). Women will be followed to ascertain maternal infectious&#xD;
      outcomes and perinatal outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripartum infection/death</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Maternal peripartum infection including chorioamnionitis, endometritis, wound infection/abscess, sepsis, and death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripartum infection/death at discharge</measure>
    <time_frame>Up to hospital discharge</time_frame>
    <description>Maternal peripartum infection including chorioamnionitis, endometritis, wound infection/abscess, sepsis, and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal outcomes</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Neonatal sepsis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">756</enrollment>
  <condition>Postpartum Sepsis</condition>
  <condition>Postpartum Endometritis</condition>
  <condition>Postpartum Fever</condition>
  <arm_group>
    <arm_group_label>Azithromycin and amoxicillin placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive 1 gram oral azithromycin as a single dose and amoxicillin placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin + amoxicillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive 1 gram oral azithromycin and 2 grams oral amoxicillin in a single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will consist of routine care at the clinical sites (which is usually no antibiotic). They will receive placebo (for azithromycin) and placebo (for amoxicillin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin tablet</description>
    <arm_group_label>Azithromycin and amoxicillin placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin and amoxicillin</intervention_name>
    <description>azithromycin and amoxicillin</description>
    <arm_group_label>Azithromycin + amoxicillin</arm_group_label>
    <other_name>azithromycin, amoxicillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Azithromycin and amoxicillin placebo</arm_group_label>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women ≥ 37 weeks' viable singleton or twin gestation in labor planning a vaginal&#xD;
             delivery with&#xD;
&#xD;
               1. Prolonged membrane rupture (≥8 hours) or&#xD;
&#xD;
               2. Prolonged labor (≥18 hours).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical chorioamnionitis or any other active bacterial infection (e.g.&#xD;
             pyelonephritis, pneumonia, abscess) at time of randomization: because standard&#xD;
             antibiotic therapy for these conditions may confound trial intervention.&#xD;
&#xD;
          -  Allergy to azithromycin or amoxicillin&#xD;
&#xD;
          -  Plan for cesarean delivery prior to enrollment&#xD;
&#xD;
          -  Fetal demise or major congenital anomaly: Major congenital anomalies may confound&#xD;
             assessment of neonatal outcomes and every attempt will be made up front to exclude&#xD;
             them from randomization. However, some unrecognized fetal anomalies may inevitably be&#xD;
             randomized. These will not be excluded post-randomization from the primary (maternal&#xD;
             outcome) analysis; they will be taken into consideration in the secondary analyses of&#xD;
             neonatal outcomes.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Tita, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cameroon Baptist Convention Health Services</name>
      <address>
        <city>Bamenda</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <reference>
    <citation>Tita ATN, Boggess K, Saade G. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. N Engl J Med. 2017 Jan 12;376(2):182. doi: 10.1056/NEJMc1614626.</citation>
    <PMID>28076707</PMID>
  </reference>
  <reference>
    <citation>WHO. WHO recommendations for prevention and treatment of maternal peripartum infections. Sept 2015 http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/peripartum-infections-guidelines/en/</citation>
  </reference>
  <results_reference>
    <citation>Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96.</citation>
    <PMID>10196487</PMID>
  </results_reference>
  <results_reference>
    <citation>ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. American Society of Health-System Pharmacists. Am J Health Syst Pharm. 1999 Sep 15;56(18):1839-88. Review.</citation>
    <PMID>10511234</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>August 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Alan Tita</investigator_full_name>
    <investigator_title>Professor and Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Puerperal Infection</mesh_term>
    <mesh_term>Endometritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 16, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

